well here's FACT just weighing in on MYOG .....Myogen, Inc-MYOG reit Strong Buy on positive Aries-1 results@FACT Ambrisentan's second Phase III study for PAH did not make statistical significance on time to clinical worsening by the firm believes the FDA will allow a combined Aries-1 and Aries-2 analysis for that specific endpoint, which would then show statistical significance. The firm believes the results provided today confirms Ambrisentan as the best-in-class agent.